Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Nymox End of Q2 New Investor Presentation on Website | ||
| By: Nasdaq / GlobeNewswire - 25 Jun 2019 | Back to overview list |
|
HASBROUCK HEIGHTS, N.J., June 25, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide an up-to-date investor communication presentation posted on the Nymox website today as the end of second quarter update for shareholders. The new company presentation is on the Nymox website (www.nymox.com) under Investors, and Company Presentation. In addition, the Company management will be available for further discussion and clarifications by contacting Erik Danielsen, Nymox CFO at info@nymox.com or by telephone at 800-936-9669 (the new presentation and telephone follow-up will replace the teleconference for this quarter). For more information please contact info@nymox.com or 800-936-9669. Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports. For Further Information Contact: |
||
|
||
 | Back to overview list | |